The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Who May Qualify: - Provision of signed and dated willing to sign a consent form form - Adults (18 years or older) - Cognitively impaired adults are not excluded (i.e. will be included in the study) - Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs) - EEG consistent with focal or generalized epilepsy - Patients must have \>4 focal aware, focal impaired aware, focal to bilateral tonic clonic or generalized tonic clonic seizures per month. - Patients can be on \>/= 1 anti-seizure medication (ASM) at the time of enrollment on stable doses 12 weeks prior to initiation - Patients on Epilepsy devices: Vagal nerve stimulator (VNS), Deep brain stimulator (DBS) or Responsive Nerve Stimulator (RNS) must have remained stable for at least 4 weeks before the screening visit. Adjustment of devices is not allowed during the study. Exclusion Criteria - Patients \<18 years of age - Pregnant women - Women that are breast feeding - Patients who had \>21 days of seizure freedom in the last year. - Patients with a history of status epilepticus within 3 months of screening - Patients with a history of alcoholism of drug misuse within the last 2 years - Unstable medical illness - Serious or imminent suicidal or homicidal risk - Patients with cardiovascular disease - Patients with schizophrenia - Patients with history of aneurysm or aortic dissection, arteriovenous malformation and intracerebral hemorrhage - Patients that are immobile i.e. wheel chair bound, bed ridden individuals - Patients on psychostimulants (amphetamines, methylphenidate etc.) and Monoamine oxidase inhibitors (selegiline, isocarboxazid, phenelzine etc.) Always talk to your doctor about whether this trial is right for you.